Abstract
Invasive fungal sinusitis has been reported from all over the world, but its incidence varies widely with higher frequency reported in Sudan [1], southwestern states of the USA, and India, which have a hot and dry climate. The incidence seems to be higher in India than elsewhere in the world [2]. The true incidence of mucormycosis is unknown and probably underestimated due to the difficulties in antemortem diagnosis and the low autopsy rates in patients who die in the setting of either leukemia or stem cell transplant [3]. However, there is a consensus that there has been an overall increase in the incidence of all types of fungal sinusitis [2, 4]. At M.D. Anderson Cancer Center, Texas, the number of reported cases increased from 8 per 100,000 admissions during 1989–1993 to 17 per 100,000 admissions during 1994–1998 [4].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Veress B, Malik OA, Tayeb AA, El Daoud S, El Mahgoub S, El Hassan AM. Further observations on the primary paranasal Aspergillus granuloma in Sudan. Am J Trop Med Hyg. 1973;22:765–72.
Chakrabarti A, Sharma SC. Paranasal sinus mycoses. Indian J Chest Dis Allied Sci. 2000;42:293–304.
Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15 year period (1989–2003). Haematologica. 2006;91(7):986–9.
Kontoyiannis DP, Wessel VC, Bodey GP, Rolston VI. Zygomycosis in the 1990s in a tertiary care cancer center. Clin Infect Dis. 2000;30:851–6.
Talmi YP, Goldschmeid-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127:22–31.
Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med. 1996;35:540–4.
Chakrabarti A, Sharma SC, Chander J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg. 1992;107:745–50.
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31–47.
Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460–6.
Mileshkin L, Slavin M, Seymour JF, McKenzie A. Successful treatment of rhinocerebral zygomycosis using liposomal nystatin. Leuk Lymphoma. 2001;42:1119–23.
Wueppenhorst N, Lee M-K, Rappold E, Kayser G, Beckervordersandforth J, de With K, Serr A. Rhino-orbitocerebral zygomycosis caused by Conidiobolus incongruous in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4322–5. doi: 10.1128/JCM.01188-10. Epub 2010 Sep 22.
Hejny C, Kerrison JB, Newman NJ, Stone CM. Rhino-orbital mucormycosis in a patient with acquired immunodeficiency syndrome (AIDS) and neutropenia. Am J Ophthalmol. 2001;132:111–2.
Lehrer RI, Howard DH, et al. Mucormycosis. Ann Intern Med. 1980;9:93–108.
Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogenic bone transplant recipients. Clin Infect Dis. 2001;32:1319–24.
Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high risk hematologic malignancies and recipients of allogenic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303–6.
Morduchowicz G, Shmueli D, Shapira Z, et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of literature. Rev Infect Dis. 1986;8:441–6.
Jimenez C, Lumbreras C, Paseiro G, et al. Treatment of mucor infection after liver or pancreas-kidney transplantation. Transplant Proc. 2002;34:82–3.
Trifilio SM, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425.
Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis. Report of four cases and review. Rev Infect Dis. 1989;11:741–54.
Espinel-Ingroff A, Oakley LA, Kerkering TM. Opportunistic zygomycotic infections. Mycopathologica. 1987;97:33–41.
Boelaert JR, Fenves AZ, Coburn JW. Mucormycosis among patients on dialysis. N Engl J Med. 1989;321:190–1.
Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med. 1989;87:468–71.
Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012;97(10):1459–70.
Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and mycobacterium tuberculosis infection. J Clin Virol. 2001;20(3):123–6.
Schaible UE, Kauffman SH. Iron and microbial infection. Nat Rev Microbiol. 2004;2(12):946–53.
Boelaert JR, Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–86.
Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and deferoxamine on Rhizopus infection. Mycopathologica. 1990;110:87–90.
Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55(3):251–8.
Boelaert JR Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host’s iron status on tuberculosis. J Infect Dis. 2007;195(12):1745–53.
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Mycopathologica. 1990;110:87–90.
Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621–7.
Garcia-Covarrubias L, Bartlett R, Bartlett DM, Wasserman RJ. Rhino-orbito-cerebral mucormycosis attributed to Apophysomyces elegans in an immunocompetent individual: a case report and review of literature. J Trauma. 2001;50:353–7.
Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997–2020.
Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect. 2009;15(50):93–7.
Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus active anti fungal therapy: a case controlled observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.
Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.
Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev. 2005;18(3):556–69.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.
Kontoyiannis DP, Lewis RE. Invasive zygomycosis: an update on pathogenesis, clinical manifestations and management. Infect Dis Clin North Am. 2006;20(3):581–607.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer India
About this chapter
Cite this chapter
Mankekar, G. (2014). Epidemiology, Pathogenesis, and Risk Factors. In: Mankekar, G. (eds) Invasive Fungal Rhinosinusitis. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1530-1_3
Download citation
DOI: https://doi.org/10.1007/978-81-322-1530-1_3
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1529-5
Online ISBN: 978-81-322-1530-1
eBook Packages: MedicineMedicine (R0)